INVESTORS

Press Releases

Year

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

May 21, 2026

- Webcast with Hepatitis B experts to discuss new biopsy and clinical data from the ongoing ELIMINATE-B trial in chronic hepatitis B - - Webcast will be held May 27 th, 2026, at 8:00 AM EDT - DURHAM, N.C. --(BUSINESS WIRE)--May 21, 2026-- Precision BioSciences, Inc....

Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

May 14, 2026

– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile mice – – Findings further support evaluation of PBGENE-DMD in DMD patient populations as young...

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026

- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver Congress 2026 - - Advanced PBGENE-DMD toward clinical evaluation in the Phase 1/2...

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

April 30, 2026

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 30, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial...

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

April 29, 2026

- Arkansas Children’s Hospital activated as the first clinical trial site and now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 29, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel...

Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

April 28, 2026

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 28, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical data from...

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

April 24, 2026

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 24, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on April 20, 2026, the...

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

April 22, 2026

- Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 22, 2026-- Precision BioSciences, Inc....

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

April 15, 2026

- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 15, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to...

Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 8, 2026

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 8, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the Company will participate in...

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 19

Investors

Events & Presentations
Press Releases
Corporate Deck
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Sustainability
Investor FAQs

Investor Tools

Print Page
Email Alerts
Contact IR
RSS Feeds

INVESTORS

Press Releases

Investors

Investor Tools

Contact Info

Learn More

Policies